UK markets closed

Sangamo Therapeutics, Inc. (SGMO)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
0.6496+0.0409 (+6.72%)
At close: 04:00PM EDT
0.6670 +0.02 (+2.68%)
After hours: 07:49PM EDT
Show:
Income statement
Balance sheet
Annual

Cash flow

All numbers in thousands
Breakdown
ttm
31/12/2023
31/12/2022
31/12/2021
31/12/2020
Cash flows from operating activities
Net income
-328,053
-257,831
-192,278
-178,286
-120,996
Depreciation & amortisation
19,137
22,192
20,562
17,638
13,369
Deferred income taxes
-
-6,335
0
0
-
Stock-based compensation
21,805
27,363
31,650
32,956
25,708
Change in working capital
-14,115
-164,034
-82,319
-101,895
252,586
Accounts receivable
6,335
2,755
2,335
-789
31,685
Other working capital
-218,160
-245,997
-243,798
-256,529
155,161
Other non-cash items
-
1,119
-
-6,497
-
Net cash provided by operating activities
-207,205
-224,842
-223,627
-233,251
169,875
Cash flows from investing activities
Investments in property, plant and equipment
-
-21,155
-20,171
-23,278
-14,714
Acquisitions, net
-
0
0
-119
-704
Purchases of investments
-23,326
-59,551
-277,391
-338,159
-570,779
Sales/maturities of investments
187,924
234,237
356,847
609,755
314,570
Net cash used for investing activities
153,643
153,531
59,285
248,199
-271,627
Cash flows from financing activities
Common stock issued
28,519
15,106
84,869
27,099
142,526
Other financing activities
-746
-1,453
-2,104
-3,258
-765
Net cash used provided by (used for) financing activities
28,708
14,588
84,660
32,858
153,100
Net change in cash
-24,408
-55,240
-78,428
47,543
50,901
Cash at beginning of period
79,741
101,944
180,372
132,829
81,928
Cash at end of period
54,887
46,704
101,944
180,372
132,829
Free cash flow
Operating cash flow
-207,205
-224,842
-223,627
-233,251
169,875
Capital expenditure
-
-21,155
-20,171
-23,278
-14,714
Free cash flow
-218,160
-245,997
-243,798
-256,529
155,161